{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:56:20Z","timestamp":1790898980920,"version":"4.1.0"},"reference-count":72,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T00:00:00Z","timestamp":1335139200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0034914","type":"journal-article","created":{"date-parts":[[2012,4,23]],"date-time":"2012-04-23T21:37:03Z","timestamp":1335217023000},"page":"e34914","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["Dasatinib as a Bone-Modifying Agent: Anabolic and Anti-Resorptive Effects"],"prefix":"10.1371","volume":"7","author":[{"given":"Antonio","family":"Garcia-Gomez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique M.","family":"Ocio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvan","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Santamaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Hern\u00e1ndez-Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fermin M.","family":"Sanchez-Guijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Hern\u00e1ndez-Iglesias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas G.","family":"Bri\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Fisac-Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atanasio","family":"Pandiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Garayoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,4,23]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future.","volume":"377","author":"TD Rachner","year":"2011","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1158\/1078-0432.CCR-10-0600","article-title":"Novel bone-targeted strategies in oncology.","volume":"16","author":"S Vallet","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction.","volume":"11","author":"KN Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/138920109787847493","article-title":"Multiple myeloma bone marrow niche.","volume":"10","author":"GW Basak","year":"2009","journal-title":"Curr Pharm Biotechnol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2010.08141.x","article-title":"Advances in the understanding of myeloma bone disease and tumour growth.","volume":"149","author":"S Yaccoby","year":"2010","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2010.06.029","article-title":"Tumor-host cell interactions in the bone disease of myeloma.","volume":"48","author":"JA Fowler","year":"2011","journal-title":"Bone"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma.","volume":"21","author":"J Corre","year":"2007","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.exphem.2009.11.009","article-title":"Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.","volume":"38","author":"K Todoerti","year":"2010","journal-title":"Exp Hematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.","volume":"1","author":"R Capdeville","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity.","volume":"26","author":"MW Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1182\/blood-2007-07-104281","article-title":"Long-term imatinib therapy promotes bone formation in CML patients.","volume":"111","author":"S Fitter","year":"2008","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1182\/blood-2009-08-237404","article-title":"Dysregulation of bone remodeling by imatinib mesylate.","volume":"115","author":"K Vandyke","year":"2010","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1359\/jbmr.070719","article-title":"Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.","volume":"22","author":"S O'Sullivan","year":"2007","journal-title":"J Bone Miner Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4334","DOI":"10.1182\/blood-2005-09-3568","article-title":"Imatinib as a potential antiresorptive therapy for bone disease.","volume":"107","author":"AL Dewar","year":"2006","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"vi42","DOI":"10.1093\/annonc\/mdm223","article-title":"Dasatinib: a new step in molecular target therapy.","volume":"18","author":"A Olivieri","year":"2007","journal-title":"Ann Oncol"},{"key":"ref16","first-page":"281","article-title":"Dasatinib in chronic myeloid leukemia: a review.","volume":"5","author":"DG Aguilera","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/leu.2008.356","article-title":"Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis.","volume":"23","author":"K Vandyke","year":"2009","journal-title":"Leukemia"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/leu.2008.237","article-title":"Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor.","volume":"23","author":"N Brownlow","year":"2009","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/onc.2010.73","article-title":"Src family kinase\/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.","volume":"29","author":"YC Lee","year":"2010","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2407-10-298","article-title":"The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts.","volume":"10","author":"H Id Boufker","year":"2010","journal-title":"BMC Cancer"},{"key":"ref21","article-title":"Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.","author":"D Tibullo","year":"2011"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/leu.2010.84","article-title":"Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro.","volume":"24","author":"S Jonsson","year":"2010","journal-title":"Leukemia"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1046\/j.1365-2141.2003.04217.x","article-title":"Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase.","volume":"120","author":"K Mihara","year":"2003","journal-title":"Br J Haematol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.biomaterials.2006.02.022","article-title":"Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to 1,25-dihydroxy vitamin D3.","volume":"27","author":"L Wang","year":"2006","journal-title":"Biomaterials"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/leu.2009.65","article-title":"Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.","volume":"23","author":"M Garayoa","year":"2009","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.","volume":"8","author":"M Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"5781","DOI":"10.1158\/0008-5472.CAN-05-4186","article-title":"The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.","volume":"66","author":"P Maiso","year":"2006","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ab.2004.02.002","article-title":"An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction.","volume":"329","author":"CA Gregory","year":"2004","journal-title":"Anal Biochem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"30689","DOI":"10.1074\/jbc.M500750200","article-title":"Cooperative interactions between activating transcription factor 4 and Runx2\/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression.","volume":"280","author":"G Xiao","year":"2005","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1479-5876-2-6","article-title":"Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay.","volume":"2","author":"M Susa","year":"2004","journal-title":"J Transl Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bone.2003.11.014","article-title":"Differential growth factor control of bone formation through osteoprogenitor differentiation.","volume":"34","author":"LR Chaudhary","year":"2004","journal-title":"Bone"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1210\/endo.134.3.8119182","article-title":"Platelet-derived growth factor enhances bone cell replication, but not differentiated function of osteoblasts.","volume":"134","author":"JM Hock","year":"1994","journal-title":"Endocrinology"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1359\/jbmr.080409","article-title":"PDGF receptor beta is a potent regulator of mesenchymal stromal cell function.","volume":"23","author":"A Tokunaga","year":"2008","journal-title":"J Bone Miner Res"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1083\/jcb.151.2.311","article-title":"Decreased c-Src expression enhances osteoblast differentiation and bone formation.","volume":"151","author":"M Marzia","year":"2000","journal-title":"J Cell Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1042\/BST0331313","article-title":"Two functionally distinct pools of Src kinases for PDGF receptor signalling.","volume":"33","author":"L Veracini","year":"2005","journal-title":"Biochem Soc Trans"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/nbt1328","article-title":"Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.","volume":"25","author":"M Bantscheff","year":"2007","journal-title":"Nat Biotechnol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1126\/science.1107627","article-title":"Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation.","volume":"308","author":"I Kratchmarova","year":"2005","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1210\/en.2006-1000","article-title":"p38 mitogen-activated protein kinase regulates osteoblast differentiation through osterix.","volume":"148","author":"X Wang","year":"2007","journal-title":"Endocrinology"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.bbrc.2011.10.097","article-title":"Osterix is regulated by Erk1\/2 during osteoblast differentiation.","volume":"415","author":"YH Choi","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2164-8-70","article-title":"Gene expression profiling of human mesenchymal stem cells derived from bone marrow during expansion and osteoblast differentiation.","volume":"8","author":"B Kulterer","year":"2007","journal-title":"BMC Genomics"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.cell.2006.10.018","article-title":"Wnt\/beta-catenin signaling in development and disease.","volume":"127","author":"H Clevers","year":"2006","journal-title":"Cell"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1182\/blood-2008-08-174300","article-title":"Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin\/TCF signaling.","volume":"113","author":"YW Qiang","year":"2009","journal-title":"Blood"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2008.03.037","article-title":"Osteoclast lineage and function.","volume":"473","author":"HK Vaananen","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts.","volume":"289","author":"SL Teitelbaum","year":"2000","journal-title":"Science"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bone.2006.09.023","article-title":"The molecular understanding of osteoclast differentiation.","volume":"40","author":"M Asagiri","year":"2007","journal-title":"Bone"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1126\/science.7939685","article-title":"c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.","volume":"266","author":"AE Grigoriadis","year":"1994","journal-title":"Science"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/360741a0","article-title":"Bone and haematopoietic defects in mice lacking c-fos.","volume":"360","author":"ZQ Wang","year":"1992","journal-title":"Nature"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1196\/annals.1402.071","article-title":"The role of NFAT in osteoclast formation.","volume":"1116","author":"H Takayanagi","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"6227","DOI":"10.1074\/jbc.M513885200","article-title":"Blockade of NFAT activation by the second calcineurin binding site.","volume":"281","author":"S Martinez-Martinez","year":"2006","journal-title":"J Biol Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-007-0773-9","article-title":"Involvement of alpha(v)beta3 integrins in osteoclast function.","volume":"25","author":"I Nakamura","year":"2007","journal-title":"J Bone Miner Metab"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1182\/blood.V97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.","volume":"97","author":"JH Han","year":"2001","journal-title":"Blood"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1 alpha ) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells.","volume":"101","author":"S Lentzsch","year":"2003","journal-title":"Blood"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma.","volume":"34","author":"GD Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1089\/hum.2010.115","article-title":"Bone marrow mesenchymal stem cells: historical overview and concepts.","volume":"21","author":"P Charbord","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1126\/science.284.5411.143","article-title":"Multilineage potential of adult human mesenchymal stem cells.","volume":"284","author":"MF Pittenger","year":"1999","journal-title":"Science"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.biocel.2010.12.006","article-title":"Bone marrow stromal cells (bone marrow-derived multipotent mesenchymal stromal cells) for bone tissue engineering: basic science to clinical translation.","volume":"43","author":"H Kagami","year":"2011","journal-title":"Int J Biochem Cell Biol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/stem.546","article-title":"Concise review: Insights from normal bone remodeling and stem cell-based therapies for bone repair.","volume":"28","author":"S Khosla","year":"2010","journal-title":"Stem Cells"},{"key":"ref58","first-page":"15","article-title":"Orthopaedic applications of bone graft &amp; graft substitutes: a review.","volume":"132","author":"SK Nandi","year":"2010","journal-title":"Indian J Med Res"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3727\/096368909X480323","article-title":"Transplantation of mesenchymal stem cells exerts a greater long-term effect than bone marrow mononuclear cells in a chronic myocardial infarction model in rat.","volume":"19","author":"M Mazo","year":"2010","journal-title":"Cell Transplant"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.","volume":"12","author":"FR Luo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/jbmr.85","article-title":"The tyrosine kinase inhibitor dasatinib dysregulates bone remodelling through inhibition of osteoclasts in vivo.","volume":"25","author":"K Vandyke","year":"2010","journal-title":"J Bone Miner Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.107.018267","article-title":"Metabolism and disposition of dasatinib after oral administration to humans.","volume":"36","author":"LJ Christopher","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","article-title":"Osteoporosis.","volume":"367","author":"P Sambrook","year":"2006","journal-title":"Lancet"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","article-title":"Increased Dickkopf-1 expression in breast cancer bone metastases.","volume":"97","author":"N Voorzanger-Rousselot","year":"2007","journal-title":"Br J Cancer"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/leu.2008.336","article-title":"Pathogenesis of myeloma bone disease.","volume":"23","author":"GD Roodman","year":"2009","journal-title":"Leukemia"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1080\/10428190701593644","article-title":"Mesenchymal stem cell abnormalities in patients with multiple myeloma.","volume":"48","author":"L Garderet","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1","article-title":"Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.","volume":"91","author":"SR Wallace","year":"2001","journal-title":"Cancer"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3109\/10428190903503438","article-title":"Osteoblastogenesis and tumor growth in myeloma.","volume":"51","author":"S Yaccoby","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","article-title":"Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.","volume":"108","author":"N Giuliani","year":"2006","journal-title":"Blood"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2007-10-116590","article-title":"Validation of PDGFRbeta and c-Src tyrosine kinases as tumor\/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.","volume":"112","author":"AM Coluccia","year":"2008","journal-title":"Blood"},{"key":"ref71","first-page":"26","article-title":"New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.","volume":"18","author":"LS Rosen","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.","volume":"20","author":"E Terpos","year":"2009","journal-title":"Ann Oncol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0034914","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,27]],"date-time":"2019-06-27T19:34:51Z","timestamp":1561664091000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0034914"}},"subtitle":[],"editor":[{"given":"Micah","family":"Luftig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,4,23]]},"references-count":72,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0034914","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,23]]}}}